PDCD1 and metastatic melanoma: Compared to existing molecular signatures, it was concluded that the on-treatment (PASS-ON) tumor specimen signature exhibited a robust and better predictive value for metastatic melanoma patients who responded to anti-PD1 across all four datasets.